Literature DB >> 32056741

The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review.

David S Mathai1, Matthew J Meyer2, Eric A Storch2, Thomas R Kosten3.   

Abstract

OBJECTIVE: The relationship between ketamine's hallucinogenic- and dissociative-type effects and antidepressant mechanism of action is poorly understood. This paper reviewed the correlation between subjective effects defined by various psychometric scales and observed clinical outcomes in the treatment of patients with Major Depressive Disorder (MDD).
METHODS: Based on PRISMA guidelines, we reviewed the dissociative and psychotomimetic mental state induced with ketamine during MDD treatment. Our selected studies correlated depression rating with validated scales collected at regular intervals throughout the study period such as the Clinician-Administered Dissociative States Scale (CADSS), Brief Psychiatric Rating Scale (BPRS), and the 5-Dimensional Altered States of Consciousness Rating Scale (5D-ASC). We excluded studies with bipolar depression or with repeated dosing and no single-dose phase. We included 8 of 556 screened reports.
RESULTS: Two of five CADSS studies found significant negative correlations between increases in CADSS scores and depression scores. One of six BPRS studies demonstrated correlations between BPRS scores and depression scores. The 5D-ASC's one study found no correlation with the MADRS.
CONCLUSIONS: Ketamine's dissociative and psychotomimetic effects were correlated with depression changes in 37.5% of studies, but most studies did not examine this relationship and future studies should consider this association since it appears important for MDMA and psilocybin therapies.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Depression; Dissociation; Hallucinogen; Ketamine; Psychedelic; Psychotomimetic

Mesh:

Substances:

Year:  2019        PMID: 32056741     DOI: 10.1016/j.jad.2019.12.023

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  14 in total

Review 1.  Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.

Authors:  Nina Schimmel; Joost J Breeksema; Sanne Y Smith-Apeldoorn; Jolien Veraart; Wim van den Brink; Robert A Schoevers
Journal:  Psychopharmacology (Berl)       Date:  2021-11-23       Impact factor: 4.530

Review 2.  Psychedelics in the treatment of unipolar and bipolar depression.

Authors:  Oliver G Bosch; Simon Halm; Erich Seifritz
Journal:  Int J Bipolar Disord       Date:  2022-07-05

3.  Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches.

Authors:  Raquel Bennett; Christian Yavorsky; Gary Bravo
Journal:  Front Psychiatry       Date:  2022-05-23       Impact factor: 5.435

Review 4.  Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants.

Authors:  Bashkim Kadriu; Maximillian Greenwald; Ioline D Henter; Jessica R Gilbert; Christoph Kraus; Lawrence T Park; Carlos A Zarate
Journal:  Int J Neuropsychopharmacol       Date:  2021-01-20       Impact factor: 5.176

Review 5.  The role of dissociation in ketamine's antidepressant effects.

Authors:  Elizabeth D Ballard; Carlos A Zarate
Journal:  Nat Commun       Date:  2020-12-22       Impact factor: 14.919

6.  Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy.

Authors:  Lauren Lepow; Hirofumi Morishita; Rachel Yehuda
Journal:  Front Neurosci       Date:  2021-09-20       Impact factor: 4.677

Review 7.  Novel Insights Into the Neurobiology of the Antidepressant Response From Ketamine Research: A Mini Review.

Authors:  Michael Colla; Hanne Scheerer; Steffi Weidt; Erich Seifritz; Golo Kronenberg
Journal:  Front Behav Neurosci       Date:  2021-12-03       Impact factor: 3.558

8.  Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report.

Authors:  Júlia Vendrell-Serres; Óscar Soto-Angona; Amanda Rodríguez-Urrutia; Gara Arteaga-Henríquez; Josep A Ramos-Quiroga
Journal:  Ther Adv Psychopharmacol       Date:  2021-06-16

9.  Rewarding Subjective Effects of the NMDAR Antagonist Nitrous Oxide (Laughing Gas) Are Moderated by Impulsivity and Depressive Symptoms in Healthy Volunteers.

Authors:  Sunjeev K Kamboj; Hannah Zhao; Luzia Troebinger; Giulia Piazza; Emma Cawley; Vanessa Hennessy; Georges Iskandar; Ravi K Das
Journal:  Int J Neuropsychopharmacol       Date:  2021-07-23       Impact factor: 5.176

Review 10.  Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies.

Authors:  Joost J Breeksema; Alistair R Niemeijer; Erwin Krediet; Eric Vermetten; Robert A Schoevers
Journal:  CNS Drugs       Date:  2020-09       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.